title: The evolving landscape of combination therapy for pulmonary arterial hypertension.
abstract: Pulmonary arterial hypertension (PAH) is a progressively fatal disease, and the goal in treatment is to prevent disease progression. The standard of care often involves medications from multiple therapeutic classes, and there has been significant interest both in the choice of agent as well as the timing of initiation. There is a growing body of support for starting multiple medications at the time of diagnosis, or 'upfront ', rather than using sequential addition to prevent clinical deterioration.
authors.affiliation: Yale University School of Medicine Ringgold Standard Institution - Internal Medicine, New Haven, CT, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Griffin
authors.affiliation: Yale Pulmonary Vascular Disease Program, Yale University School of Medicine Ringgold Standard Institution - Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, 333 Cedar Street PO Box 208057, New Haven, CT 06510-8057, USA.
authors.forename: Terence K
authors.initials: TK
authors.lastname: Trow
mesh_terms: D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D058990:Molecular Targeted Therapy; D013997:Time Factors
keywords: combination therapy; endothelin receptor antagonist; phosphodiesterase inhibitor; prostacyclin; pulmonary arterial hypertension; upfront therapy